Coloplast cuts annual organic revenue growth outlook through 2030 to 5-7% from 7-8%
Bitget2026/11/02 16:20- Coloplast cut its annual organic revenue growth ambition through FY 2029/30 to 5-7% from 7-8%.
- The revised outlook targets a constant-currency EBIT margin in the mid-20% range, with ROIC around 20%, previously above 20%.
- For FY 2026/27, organic revenue growth is forecast at 5-7%; constant-currency EBIT margin before special items is expected around 25%.
- The downgrade reflects US biologics reimbursement changes, healthcare pricing pressure, inflation and increased investment in innovation and selected commercial areas.
- A cost-saving program aims to free up around DKK 500 million, reaching full impact in FY 2027/28.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
Crypto prices
More
